Figure 1.

Schematic of a patient pathway in lung cancer outlining the barriers to implementing diagnostic biomarker testing at each stage of the pathway for the different stakeholder groups: HCPs, patients, diagnostic labs, and payers. COVID‐19, coronavirus disease 2019; HCP, healthcare professional.